OPDP slams Kowa for Lipofen-touting email; Pharma responds to FDA's social media rules; Novo nabs EU approval for Xultophy;

> The FDA's Office of Prescription Drug Promotion jumped on Kowa Pharmaceuticals and Cipher Pharmaceuticals ($CPHMF) for "unsubstantiated claims" in an email promoting its cholesterol treatment Lipofen. Report

> Drugmakers aren't happy about the FDA's new social media rules, and they've filed their grievances with the agency as part of the rulemaking process. Report

> Novo Nordisk's ($NVO) new combination diabetes treatment Xultophy, comprising Tresiba and Victoza, won approval in Europe; the company plans to launch early next year. Release

> AstraZeneca ($AZN) posted new trial data on Bydureon, its long-acting version of exanatide, showing that it matched or beat the twice-daily version, Byetta, at helping people with diabetes control their blood sugar. Report

> Spectrum Pharmaceuticals ($SPPI) licensed two of its cancer drugs, Zevalin and Marqibo, and a Phase III candidate to CASI Pharmaceuticals ($CASI) to develop and sell in China. Report

And Finally... Merck ($MRK) and Bristol-Myers Squibb ($BMY) may be wrapping up their Sustiva patent fight with Cipla, according to newly filed court documents. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?